COMMUNIQUÉS West-GlobeNewswire
-
SafeSpace Global Secures Shareholder Approval to Increase Authorized Shares of Common Stock
23/03/2026 -
AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass
23/03/2026 -
Standard Dental Labs Inc. Engages Strategic Advisor to Support Lab Acquisition Strategy
23/03/2026 -
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
23/03/2026 -
Cortexa Advances Commercialisation of MDMA Supply in Australia
23/03/2026 -
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
23/03/2026 -
Children’s National launches Division of AI Research to lead the future of artificial intelligence in pediatric medicine
23/03/2026 -
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
23/03/2026 -
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
23/03/2026 -
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
23/03/2026 -
CareMore Health Announces Appointment of Dr. Anh Pham as Chief Medical Officer
23/03/2026 -
Vantive Accelerates U.S. Home Therapy Transformation With New Digital and Patient Support Innovations
23/03/2026 -
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
23/03/2026 -
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
23/03/2026 -
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
23/03/2026 -
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
23/03/2026 -
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
23/03/2026 -
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
23/03/2026 -
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
23/03/2026
Pages